A high-level overview of Relay Therapeutics, Inc. (RLAY) stock. The companyâs stock price has collected 25.75% of gains in the last five trading sessions. Get the hottest stocks to ⦠They presently have a $57.00 target price on the stock, up from their prior target price of $54.00. For matters related to stock certificates, please contact Relay Therapeuticsâ transfer agent: Computershare PO Box 505000 Louisville, KY 40233 Toll-free Phone: 1-800-736-3001 International Phone: 1-781-575-3100 The Relay Therapeutics IPO pricing gave it a market valuation of about $1.8 billion. Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today announced the pricing of its initial public offering of 20,000,000 shares of its common stock at a price to the public of $20.00 per share. Relay Therapeutics Inc. RLAY 50.93 0.01 (0.02%). Investors Business Daily - 4 months ago Shares of Relay Therapeutics Inc. RLAY, +67.10% sprinted out of the gate Thursday, after the clinical-stage oncology company's upsized initial public offering priced above the expected range. It focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. Shares of Relay Therapeutics Inc. RLAY, +67.10% sprinted out of the gate Thursday, after the clinical-stage oncology company's upsized initial public offering priced above the expected range. Dive deeper with interactive charts and top stories of Relay Therapeutics Inc. Relay Therapeutics Stock. Relay Therapeutics Inc (RLAY) Interactive Stock Chart analysis - view dynamic stock charting for Relay Therapeutics Inc Add to watchlist Start Trading >> News. GlobeNewswire. Relay Therapeutics Inc. stock down 0.05% on Friday (Updated on October 30, 2020) Sell candidate since 2020-10-23 Loss -7.37% PDF Last Trading Session. Relay Therapeutics's stock sprints out of the gate, after upsized IPO priced above recently raised expectations. View Relay Therapeutics, Inc. RLAY investment & stock information. Relay Therapeutics Inc Registered Shs Stock , RLAY. In recent trading, shares of Relay Therapeutics Inc (Symbol: RLAY) have crossed above the average analyst 12-month target price of $46.00, changing hands for $47.35/share. View today's stock price, news and analysis for Relay Therapeutics Inc. (RLAY). RLAY Stock Predictions, Articles, and Relay Therapeutics Inc News From the Web The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback Get the latest Relay Therapeutics, Inc. RLAY detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Relay Therapeutics Inc is a precision medicines company focused on enhancing small molecule therapeutic discovery in targeted oncology. Relay Therapeutics (NASDAQ:RLAY) âs stock had its âbuyâ rating reissued by equities research analysts at HC Wainwright in a report issued on Tuesday, The Fly reports. GlobeNewswire 09/03/20. After pricing at $20, Relay stock catapulted 75.3%, closing at 35.05 on the stock market today. Company profile page for Relay Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information Funding History. RLAY, Relay Therapeutics Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines View the latest RLAY stock quote and chart on MSN Money. View the latest Relay Therapeutics Inc. (RLAY) stock price, news, historical charts, analyst ratings and financial information from WSJ. Access detailed information about the Relay Therapeutics Inc (RLAY) Share including Price, Charts, Technical Analysis, Historical data, Relay Reports and more. Relay was built upon unparalleled insights into protein motion and how this dynamic behavior relates to protein function. MarketWatch. Relay Therapeutics, Inc. Common Stock (RLAY) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Relay Therapeutics Inc. (NASDAQ:RLAY) went up by 10.00% from its latest closing price compared to the recent 1-year high of $49.89. Item 1.01 Entry into a Definitive Material Agreement. Relay Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Trial of RLY-4008, a Highly Selective FGFR2 Inhibitor. Relay Therapeutics was founded on the premise that putting protein motion at the heart of drug discovery can dramatically expand therapeutic possibilities. Relay Therapeutics, Inc. is a clinical-stage precision medicines company. September 2016: $57.0M: December 2017: Official Close 10/23/2020 NAS. When a stock ⦠and has now fallen 4 days in a row.During the day the stock fluctuated 5.29% from a day low at $36.01 to a day high of $37.91. The average 12-month [â¦] The Relay Therapeutics Inc. stock fell by -0.05% on the last day (Friday, 30th Oct 2020) from $36.96 to $36.94. Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) have received a consensus rating of âBuyâ from the seven research firms that are presently covering the firm, MarketBeat.com reports. 07:34AM : Relay Therapeutics upsizes and ⦠Get instant access to a free live streaming chart of the Relay Therapeutics Inc Stock. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. On December 11, 2020, Relay Therapeutics, Inc. (the "Company") entered into a Collaboration and License Agreement (the "Agreement") with Genentech, Inc. ("Genentech") and F. Hoffmann-La Roche Ltd (together with Genentech, "Licensee").Pursuant to the Agreement, the Company and Licensee will collaborate on ⦠About Relay Therapeutics Stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process. Webull offers Relay Therapeutics, Inc. (RLAY) historical stock prices, in-depth market analysis, NASDAQ: RLAY real-time stock quote data, in-depth charts, and ⦠Get Relay Therapeutics Inc (RLAY:NASDAQ) real-time stock quotes, news and financial information from CNBC. Analyze the movement of proteins inside human cells. IBD Newsletters Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.The company's platform detects and characterizes interactions that occur anywhere on a protein and combines computational methods with experimental approaches across the fields of structural biology, Relay Therapeutics Inc. historical stock charts and prices, analyst ratings, financials, and todayâs real-time RLAY stock price. Relay Therapeutics Inc Stock Institutional Ownership and Insider Ownership - : the historical trend of stock ownership among institutions and insiders. Post-Market 0.00 (0.00%) These insights enable us to effectively drug protein targets that have previously been intractable (i.e. Jul-15-20 08:51PM : Relay Therapeutics Announces Pricing of Initial Public Offering. 39.88-0.39-0.97%. Investors Business Daily - 4 months ago HC Wainwrightâs price objective indicates a potential upside of 30.08% from the stockâs current price.
Varian Johnson Biography, Akula Gta 5, How To Rate An App Ios 13, What Happened To Ac Milan, April Rose Pengilly Botox, How To Turn Off Rush Hour On Nest, Dr John Forbes Stuarts Draft Va Obituary, ,Sitemap
Recent Comments